天士力：12月9日召开董事会会议

Group 1 - The core point of the article is that Tian Shi Li (SH 600535) held its 16th meeting of the 9th Board of Directors on December 9, 2025, to review proposals regarding the revision and establishment of certain corporate governance systems [1] - For the year 2024, Tian Shi Li's revenue composition is as follows: Traditional Chinese medicine accounts for 70.89%, chemical preparations for 15.38%, pharmaceutical commerce for 10.53%, biological drugs for 2.25%, and chemical raw materials for 0.61% [1] - As of the report date, Tian Shi Li's market capitalization is 22.7 billion yuan [1] Group 2 - The article also highlights a significant issue in the pharmaceutical industry regarding the abuse of pregabalin, marking the first reported case of addiction in China, which raises concerns about the accessibility of prescription drugs without proper medical records [1]